Repligen Corporation (RGEN)
NASDAQ: RGEN · Biological Products, (No Diagnostic Substances) · Waltham, MA
Our rating: Neutral
Call changed from Cautious to Neutral at $172.95, moderate conviction, November 2, 2026.
Breaks if: The Neutral view turns Cautious if year-over-year revenue growth decelerates below 10% in either of the next two reported quarters, signaling the recovery thesis is losing steam at a multiple this demanding. It turns Positive if revenue growth holds above 25% for two consecutive quarters and trailing FCF reaches $150M or more within four quarters, indicating that underlying earnings power is closing the gap with the market capitalization at a visible pace.
Key figures
| Market value | $10.5B |
|---|---|
| Revenue, last 12 months | $806M |
| Net income, last 12 months | −$12M |
| Free cash flow, last 12 months | $107M |
| Price to earnings | n/a |
| Free cash flow yield | 1.0% |
| Dividend yield | 0.0% |
| Operating margin | 2.3% |
| Return on equity | −0.6% |
| Beta to the S&P 500 | 1.30 |
| Volatility, annualized | 50.3% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $209M | 10.9% | $-0.68 | $38M |
| June 30, 2026 | $204M | 11.9% | $0.09 | $27M |
| March 31, 2026 | $194M | 14.8% | $0.15 | $24M |
| December 31, 2025 | $198M | 18.1% | $0.23 | $18M |
| September 30, 2025 | $189M | 21.9% | $0.26 | $43M |
| June 30, 2025 | $182M | 14.8% | $0.26 | $22M |
| March 31, 2025 | $169M | 10.4% | $0.10 | $11M |
| December 31, 2024 | $168M | 0.6% | $-0.61 | $34M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.23B: Claude 38%, Gemini 35%, Mistral 40%
- Diluted earnings per share are at least $0.23: Claude 35%, Gemini 5%, Mistral 20%
- Free cash flow for the quarter is at least $0.02B: Claude 65%, Gemini 90%, Mistral 85%
15 ledger entries and 64 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.